Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dopamine Receptor Occupancy”

25 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 25 results

Post-approval studies (Phase 4)Study completedNCT00302367
What this trial is testing

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

Who this might be right for
Healthy Volunteers
Massachusetts General Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT02815917
What this trial is testing

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

Who this might be right for
D3 Dopamine ReceptorCocaine-dependentHealthy Volunteer
University of Pennsylvania 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07626034
What this trial is testing

A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398

Who this might be right for
Schizophrenia Disorder
Shanghai Zhongze Therapeutics Co., Ltd. 9
Post-approval studies (Phase 4)WithdrawnNCT05060549
What this trial is testing

Dopamine D3 Receptor Occupancy in Bipolar Depression

Who this might be right for
Bipolar Depression
New York State Psychiatric Institute
Not applicableStudy completedNCT01660880
What this trial is testing

Validation of Receptor Occupancy Simulation

Who this might be right for
Dopamine Receptor OccupancyMedication SatisfactionProlactin Level+1 more
Seoul National University Hospital 7
Early research (Phase 1)Study completedNCT02093169
What this trial is testing

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

Who this might be right for
Healthy Men
H. Lundbeck A/S 12
Not applicableUnknownNCT02880995
What this trial is testing

[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis

Who this might be right for
Schizophrenia
Seoul National University Hospital 62
Not applicableStudy completedNCT00818298
What this trial is testing

24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study

Who this might be right for
SchizophreniaSchizoaffective Disorder
Centre for Addiction and Mental Health 12
Large-scale testing (Phase 3)Study completedNCT00302393
What this trial is testing

Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults

Who this might be right for
Healthy
Massachusetts General Hospital 20
Early research (Phase 1)Study completedNCT00468806
What this trial is testing

Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.

Who this might be right for
Healthy Subjects
GlaxoSmithKline 25
Early research (Phase 1)Study completedNCT04588129
What this trial is testing

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

Who this might be right for
Schizophrenia
LB Pharmaceuticals Inc. 16
Early research (Phase 1)Study completedNCT00814957
What this trial is testing

An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand

Who this might be right for
Substance Dependence
GlaxoSmithKline 12
Early research (Phase 1)Study completedNCT02333487
What this trial is testing

Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

Who this might be right for
Schizophrenia
H. Lundbeck A/S 22
Early research (Phase 1)Study completedNCT00832221
What this trial is testing

Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL

Who this might be right for
Depression
AstraZeneca 10
Post-approval studies (Phase 4)Ended earlyNCT00934635
What this trial is testing

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

Who this might be right for
Schizophrenia
Janssen-Cilag G.m.b.H 2
Testing effectiveness (Phase 2)Study completedNCT00593138
What this trial is testing

Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate

Who this might be right for
Drug Binding to DAT Receptors
Massachusetts General Hospital 23
Early research (Phase 1)Study completedNCT00796432
What this trial is testing

Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone

Who this might be right for
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4
Not applicableUnknownNCT00825045
What this trial is testing

Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia

Who this might be right for
SchizophreniaSchizoaffective DisorderSchizophreniform Disorder
Centre for Addiction and Mental Health 14
Large-scale testing (Phase 3)Study completedNCT00301639
What this trial is testing

A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults

Who this might be right for
Healthy Volunteers
Massachusetts General Hospital 40
Early research (Phase 1)Study completedNCT00269035
What this trial is testing

SPECT Study With SB-773812 In Schizophrenic Patients

Who this might be right for
Schizophrenia
GlaxoSmithKline 95
Next Page